Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05131984 · ClinicalTrials.gov registry record
Ocrelizumab Access by Socio-Economic Status
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 800
- Enrollment target
NCT05131984 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 800 participants.
The verdict
NCT05131984 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
The primary aim of this project is to determine whether there are differences in access to, efficacy and tolerability of Ocrelizumab in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS in two large academic MS Centers with a high volume of patients on Ocrelizumab. The study is a retrospective analysis of multiple sclerosis patients cared for at Brigham and Women's Hospital and Boston Medical Center who were treated with Ocrelizumab during the 4 year study period.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2023-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05131984
The ClinicalTrials.gov registry entry for NCT05131984 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT05131984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05131984 about?
NCT05131984 is a clinical study titled "Ocrelizumab Access by Socio-Economic Status". The primary aim of this project is to determine whether there are differences in access to, efficacy and tolerability of Ocrelizumab in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS in two large academic MS Centers with a high volume of patien...
What is the current status of trial NCT05131984?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2021-11-18. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT05131984?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT05131984?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.